Verici Dx Plc (VRCI) AI Stock Analysis

• Market Cap: £7.19M
• Dividend Yield: N/A
• Average Volume (3M): 6.85M
• Price to Earnings (P/E): ―
• Beta (1Y): -1.48
• Revenue Growth: -57.03%
• EPS Growth: -15.71%
• Country: UK
• Employees: 19
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): N/A
• Shares Outstanding: 1,513,394,200
• 10 Day Avg. Volume: 9,044,876
• 30 Day Avg. Volume: 6,845,005
• PEG Ratio: 0.04
• Price to Book (P/B): 2.15
• Price to Sales (P/S): 3.38
• P/FCF Ratio: -1.82
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 58 Neutral
• Price Target: 0.75 p ▲(4.72% Upside)
• Action: Reiterated Date: 12/07/25
• Date: Action: Reiterated 12/07/25

Verici Dx Plc's overall stock score is driven by positive corporate events and technical indicators, which are offset by financial performance challenges and valuation concerns. The company's strategic initiatives and market expansion efforts are promising, but ongoing profitability and cash flow issues present significant risks.

Positive Factors

Conservative balance sheet

A strong equity position and low leverage give Verici durable financial flexibility to fund commercial expansion, clinical validation and operating losses over multiple quarters without immediate insolvency risk. This conservative capital structure supports longer-term strategic initiatives and resilience to cyclical shocks.

Negative Factors

Ongoing net losses

Persistent negative EBIT and net losses mean the company is not yet generating operating profitability, pressuring returns and limiting reinvestment capacity. Over a multi-quarter horizon, sustained losses can force strategic trade-offs, slower commercial expansion or repeated external financing, diluting shareholder value.

Verici Dx Plc Business Overview & Revenue Model

Company Description

Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients. Its in-development tests include Clarava, a pre-transplant...

Read more

Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients. Its in-development tests include Clarava, a pre-transplant...

How the Company Makes Money

Verici Dx generates revenue primarily through the sale of its diagnostic tests to hospitals, transplant centers, and healthcare providers. The company benefits from a fee-for-service model, where it charges healthcare institutions for each test pe...

Read more

Verici Dx generates revenue primarily through the sale of its diagnostic tests to hospitals, transplant centers, and healthcare providers. The company benefits from a fee-for-service model, where it charges healthcare institutions for each test pe...

Verici Dx Plc Financial Statement Overview

Breakdown	Jun 2025	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.34M	1.01M	0.00	0.00	0.00
Gross Profit	3.34M	1.01M	0.00	0.00	0.00
EBITDA	-5.15M	-7.88M	-10.50M	-7.15M	-2.10M
Net Income	-5.87M	-8.73M	-11.36M	-8.33M	-7.10M
Balance Sheet
Total Assets	7.49M	7.44M	14.30M	13.79M	20.31M
Cash, Cash Equivalents and Short-Term Investments	4.06M	2.65M	9.80M	10.34M	17.75M
Total Debt	371.00K	540.00K	700.00K	0.00	73.55K
Total Liabilities	2.23M	3.88M	2.80M	1.80M	681.89K
Stockholders Equity	5.26M	3.56M	11.51M	11.98M	19.62M
Cash Flow
Free Cash Flow	-6.21M	-7.39M	-11.38M	-7.30M	-1.32M
Operating Cash Flow	-6.02M	-7.16M	-10.07M	-6.34M	-1.28M
Investing Cash Flow	61.00K	-231.00K	-1.31M	-965.86K	-237.16K
Financing Cash Flow	7.32M	-27.00K	12.67M	-73.55K	26.75M

Verici Dx Plc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.72
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:VRCI, the sentiment is Negative. The current price of 0.72 is above the 20-day moving average (MA) of 0.55, above the 50-day MA of 0.62, and above the 200-day MA of 0.71, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 1.21 is Positive, neither overbought nor oversold. The STOCH value of 23.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:VRCI.

Verici Dx Plc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EKF	66 Neutral	£100.85M	55.78	3.01%	―	-1.43%	28.57%
VRCI	58 Neutral	£7.19M	-0.39	-122.54%	―	-57.03%	-15.71%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GDR	47 Neutral	£15.25M	-1.51	-153.92%	―	90.42%	79.21%
ABDX	45 Neutral	£20.09M	-2.69	-58.27%	―	37.39%	-126.19%
OBD	40 Underperform	£8.15M	-0.25	-316.67%	―	72.17%	79.03%
RENX	39 Underperform	£8.96M	―	425.97%	―	-4.48%	61.09%

Verici Dx Plc Corporate Events